Supportive Care Measures for Patients Planning to Receive an Allogenic Transplant
January 19th 2024This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.
Hematologic Malignancies and Transplant Options and Conditioning Regimens Used in Allo-HSCT
January 19th 2024Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.
Assessing the Promise of AI in Oncology: Looking to the Future
December 25th 2023In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.
Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
December 18th 2023Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.
Assessing the Promise of AI in Oncology: Matching Patients With Clinical Trials
December 18th 2023In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.